Multi-target therapy in patients with lupus nephritis (LUPUS-KCR 2023) - May 20, 2023 - Pres time: May 19, 2023; 12:00 PM - 12:40 PM; Location: Grand Ballroom 101+102; "Sponsored by Astellas Multi-target therapy with mycophenolate mofetil (MMF), tacrolimus (TAC) to lupus nephritis (LN) was initially reported in 2008 by the Nanjing University (Bao H et al...Multi-target therapy demonstrated superior efficacy compared with intravenous cyclophosphamide as induction therapy for LN (Liu et al...Recently, multi-target therapy with MMF and novel calcineurin inhibitor (CNI), voclosporin, also showed a higher remission rate than MMF + placebo under low-dose steroid in a phase 3 trial (Rovin et al...In this session, I will show the long-term data of muti-target therapy. In addition, I will discuss the significance of multi-target therapy with MMF and CNI by comparing to the recent new combination therapy, such as MMF + belimumab."
Clinical • Glomerulonephritis • Immunology • Inflammatory Arthritis • Lupus • Lupus Nephritis • Nephrology
|